Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial
Denice S. Feig(Mount Sinai Hospital), Nashwah Taha, Edmond A. Ryan(University of Alberta), Carolyn Oldford, Michele Strom, Jon Barrett(Sunnybrook Hospital), Jennifer M. Yamamoto, Sherri A. Pockett, Vivian Zhou, Johanna Sanchez(Sunnybrook Hospital), Sylvie Daigle, Claire Gougeon(Cambridge University Hospitals NHS Foundation Trust), Elizabeth Asztalos(Sunnybrook Health Science Centre), Bi Lan Wo, Siobhan Tobin(Sunnybrook Hospital), Laurie Slater, Heidi Virtanen, Florence Weber, Abhay Lodha, David Simmons(Western Sydney University), M. Robinson, Eileen K. Hutton(McMaster University), I. George Fantus(McGill University Health Centre), George Tomlinson(Toronto General Hospital), Sophie Leblanc, Aarthi Kamath, Barbara Cleave, Lois Donovan(Unknown), Ariane Godbout, Michèle Mahone, David McIntyre(Mater Health Services), Shital Gandhi, Paul J. Karanicolas(Sunnybrook Health Science Centre), Lorraine L. Lipscombe(University of Toronto), Cheryl Verhesen, Kellie E. Murphy(Mount Sinai Hospital), Marie‐Josée Bédard, Melissa Deans, Stephanie Cooper, Simon Yu Tian(Sunnybrook Hospital), Bernard Zinman(Mount Sinai Hospital), Debbie Fong, Anthony Armson(Dalhousie University), Catherine A. Young, Diane Donat, Sora Ludwig, Afshan Zahedi(Women's College Hospital), Effie Viguiliouk
Cited by 228
Related Papers
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
|New England Journal of Medicine|2015|11.9k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
|New England Journal of Medicine|2016|3.6k
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2017|2.1k
Prevention of VTE in Nonorthopedic Surgical Patients
|CHEST Journal|2012|2.1k